BRIEF published on 11/20/2026 at 08:27, 1 day 19 hours ago GenSight Biologics raises €1.1 million from its shareholders Fundraising Clinical Trial Shareholder Support GenSight Biologics Gene Therapies
BRIEF published on 11/20/2026 at 08:27, 1 day 19 hours ago GenSight Biologics Raises EUR 1.1 Million from Existing Shareholders Shareholders Warrants Fundraising Gene Therapy Biopharma
PRESS RELEASE published on 11/20/2026 at 08:22, 1 day 19 hours ago Inside Information / Other news releases
BRIEF published on 10/08/2026 at 08:35, 1 month 13 days ago Publication of the results of the GS030 trial for retinitis pigmentosa Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa Trial Results
BRIEF published on 10/08/2026 at 08:35, 1 month 13 days ago GenSight Biologics and National Hospital Publish GS030 Trial Outcomes Gene Therapy GenSight Biologics Optogenetics Retinitis Pigmentosa GS030 PIONEER Trial
PRESS RELEASE published on 10/08/2026 at 08:30, 1 month 13 days ago Inside Information / Other news releases GenSight Biologics and 15-20 National Hospital publish NEJM article on GS030 Phase 1/2 trial results for retinitis pigmentosa treatment, showcasing promising optogenetics approach GenSight Biologics Optogenetics 15-20 National Hospital NEJM Article GS030
BRIEF published on 10/08/2026 at 07:05, 1 month 13 days ago GenSight Biologics Secures €1 Million Funding from Shareholders Shareholders Fundraising Financial Strategy GenSight Biologics Retinal Therapies
PRESS RELEASE published on 10/08/2026 at 07:00, 1 month 13 days ago Inside Information / Other news releases GenSight Biologics successfully completes €1.0 million fundraising subscribed by existing shareholders. Proceeds to be used for operational activities and working capital requirements Shareholders Working Capital Fundraising Operational Activities GenSight Biologics
BRIEF published on 10/08/2026 at 01:06, 1 month 14 days ago Financial position of GenSight Biologics as of September 30, 2026 Treasury Bridge Financing GenSight Biologics Phase III RECOVER Access Programs
BRIEF published on 09/30/2026 at 00:42, 1 month 22 days ago GenSight Biologics Reports 2026 Interim Financial Results Funding Challenges GenSight Biologics Early Access Programs Financial Results 2026 Clinical Trials Update
Published on 11/20/2026 at 15:00, 1 day 12 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 12 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 13 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 3 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 6 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 8 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 8 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 9 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 10 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 8 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 19 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing